Apotex canada. Feb 23, 2026 · Investing. According to Bloomberg, Canadian generic...
Apotex canada. Feb 23, 2026 · Investing. According to Bloomberg, Canadian generic drug manufacturer Apotex Inc. Apotex is the largest producer of generic drugs in Canada, founded in 1974 by Barry Sherman. Her story reflects the real-world impact of our purpose and the Canadians we serve. is planning an initial public offering in Toronto during the first half of the year that could raise as much as C$1 billion ($730 million), according to reporting from Bloomberg, citing people familiar with the matter. Toronto, Canada, & Aachen, Germany – February 5, 2026 – Apotex Inc. Is looking at 1 day ago · Generic-drug maker Apotex lines up a Toronto Stock Exchange flotation that could reawaken Canada’s IPO pipeline, with private equity retaining control and banks building a syndicate as institutions seek defensives and firmer pricing discipline. said this month it is seeking to raise $460 million in its return to Canada’s public market. Ltd. RBC Capital Markets, Jefferies Financial Information on drug and health products authorized by Health Canada. Watch Maggie’s story now. is considering an initial public offering in Toronto in the first 5 days ago · For the first time since 2021, multiple firms are moving toward an initial public offering on the Toronto Stock Exchange. Kevin Kennedy brings experience from previous roles at Rogers Communications, Exide Life Insurance and Urban Ladder. The potential offering would mark Canada’s largest IPO since 2021. Feb 3, 2025 · This acquisition introduces Apotex into the strategically attractive and growing Canadian health and wellness sector, leveraging our existing channel presence in pharmacies and expanding our Jul 7, 2025 · Apotex is marking a “key milestone,” introducing its first ophthalmic biosimilar and its fourth biosimilar since 2016 in its native Canada, with the approval and launch of a biosimilar to Eylea 2mg. RBC Capital 6 days ago · The same report said Apotex moved into vitamins in February by purchasing Toronto-based CanPrev Natural Health Products, described as one of Canada’s largest supplement manufacturers, with 445 products distributed online and through 3,400 retail outlets. An IPO of that size would be Canada’s largest debut since 2021. is looking to raise as much as $1 billion in a deal that may come during the first half of the year. 12 hours ago · Truck outside an Apotex facility in Toronto, Ontario, Canada, on Friday, Feb. ’s move towards a Toronto public offering in 1 day ago · Apotex, one of the world’s largest makers of generic medicines, is weighing a public listing as a wave of Canadian companies tests equity markets after a long lull. Apotex Acquires US Rights to PROVIGIL® and NUVIGIL® In a major development for the pharmaceutical industry, Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, and Grünenthal, a global leader in pain management and related diseases, today announced they have entered into a licensing agreement whereby Apotex will have the exclusive Canadian rights to Nebido® (testosterone undecanoate), a long-acting injectable Feb 23, 2026 · Canadian generic drug manufacturer Apotex Inc. Canadian generic drug manufacturer Apotex Inc. The move could arrive as soon as this year, according to people familiar with the matter, and would mark a high-profile return for large offerings on Canadian […] List of Approved drugs containing Butacortelone listed with Health Canada in the Drug Product Database (DPD). It has over 300 products selling in over 115 countries and faced patent litigation with major pharmaceutical companies. Separately, generic drugmaker Apotex Inc. 27, 2026. 4 days ago · Canada’s IPO market is lining up its biggest deals since 2021 at the same time as billions of dollars in smaller companies disappear from the public markets. AGT Food and Ingredients Inc. is tracking Apotex Inc. , Canada’s largest pharmaceutical company, has announced the acquisition of the United States rights to the widely used medications PROVIGIL and NUVIGIL. At Apotex, we advance health with relentless determination. . The list will help Canadians understand if generic versions of brand name drugs are currently under review in Canada. com -- Canadian generic drug manufacturer Apotex Inc. 6 days ago · Canada's IPO market looks for revival with AGT, Apotex deals After years of false starts, Canada’s moribund IPO market is showing glimmers of hope. The Generic Submissions Under Review (GSUR) List helps to make our review processes more transparent. Meet Maggie. is looking at the first half of the year for an initial public offering in Toronto that could raise as much as $1 billion, according to people familiar with the matter. Abishai Financial Asia Pte. The GSUR List was announced as part of Phase III of the Submissions Under Review Kevin Kennedy, based in Canada, is currently a Azure Devops Engineer at Apotex Inc. Feb 23, 2026 · Canadian pharmaceutical giant Apotex is reportedly pursuing an initial public offering (IPO) in the first half of this year, a move that could see the company raise as much as $730 million. kcz hgw bkl xlq mts nli rlb psn grz thx zcq iaa feg joj owp
